# A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia

Study · id `cardio:ct-nct07278830` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07278830](<https://clinicaltrials.gov/study/NCT07278830>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07278830

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 214 participants.

## Technical summary

Registry record NCT07278830. Randomized; quadruple masking; primary purpose treatment. Start 2023-06-02 (actual); primary completion 2024-05-24 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 214 participants (enrolled count; ClinicalTrials.gov record NCT07278830, source copy `cardio:ctgov-nct07278830-2025-12-12`, retrieved 2026-10-31)
- Started: 2023-06-02 (actual) (ClinicalTrials.gov record NCT07278830, source copy `cardio:ctgov-nct07278830-2025-12-12`, retrieved 2026-10-31)
- Primary completion: 2024-05-24 (actual) (ClinicalTrials.gov record NCT07278830, source copy `cardio:ctgov-nct07278830-2025-12-12`, retrieved 2026-10-31)
- Completion: 2024-06-07 (actual) (ClinicalTrials.gov record NCT07278830, source copy `cardio:ctgov-nct07278830-2025-12-12`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07278830, source copy `cardio:ctgov-nct07278830-2025-12-12`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07278830-2025-12-12`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia
- Condition: Hypercholesterolemia and Mixed Dyslipidemia
- Intervention (Drug): SAL003 140mg+Atorvastatin
- Intervention (Drug): SAL003 420mg+Atorvastatin
- Intervention (Drug): Placebo 140mg+Atorvastatin
- Intervention (Drug): Placebo 420mg+Atorvastatin
- Lead sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Lead sponsor class: INDUSTRY
- Collaborator: Salubris (Chengdu) Biotechnology Co., Ltd.
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. (`cardio:org-shenzhen-salubris-pharmaceuticals-co-ltd`)

## Provenance

Content hash: 3ff6492941aabd44c4b9fde1d69a2328d0fc49c09accf20d31aed46ec7b79ac1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
